Breaking
Breathwork Protocols

Drug exposes hidden lung cancer weakness

By Bennett Ashworth 3 min read
Drug exposes hidden lung cancer weakness - lung cancer weakness
OMO-103 was designed to inhibit MYC and is already being tested in patients with various cancers, including non-small cell lung cancer.

Scientists have identified a hidden weakness in a common type of lung cancer, showing that a drug meant to starve tumors of a vital protein can also make cancer cells visible to the immune system. Researchers found that the experimental drug OMO-103 not only stops cancer cell growth but also helps white blood cells find and destroy tumors.

Targeting the MYC protein

MYC is a protein that drives rapid cell division in cancer, allowing tumors to grow unchecked. For years, targeting this protein has been difficult because it sits deep inside the cell, making it hard to hit with medicine. OMO-103 was designed to inhibit MYC and is already being tested in patients with various cancers, including non-small cell lung cancer.

The study focused on non-small cell lung cancer, which makes up about 85% of all lung cancer cases. While new treatments have changed how doctors manage this disease, resistance remains a major issue. Many patients do not respond to drugs from the start, and those who do often develop resistance over time.

Signs of immune activation

Researchers analyzed samples from patients with non-small cell lung cancer that had a fault in the KRAS gene. This gene activates MYC. When the samples were treated with OMO-103 in the lab, white blood cells called CD4+ and CD8+ T cells entered the tumor tissue. These cells showed signs of activating an immune response against the cancer.

Professor Laura Soucek, who led the work, noted that removing T cells reduced the drug’s effectiveness by roughly half. This suggests that the immune system plays a significant role in the drug’s success. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

In the MYCure phase I trial, the team examined blood and tumor samples from patients receiving OMO-103. Patients who saw a clinical benefit showed activation of two immune system processes: interferon and the TNF-superfamily. These pathways help T cells survive and sustain an immune response.

Preclinical results show promise

Tests in mouse models of lung cancer supported the laboratory findings. The researchers combined OMO-103 with other immune-activating drugs and observed stronger results. Pairing the drug with an activator of the OX40 protein raised the objective response rate from 37% to 89%. Combining it with a 4-1BB activator increased the response rate from 29% to 100%, with two of the seven animals showing complete tumor disappearance.

Bennett Ashworth

Leave a Reply

Your email address will not be published. Required fields are marked *